RecruitingNCT05683379
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to <25 Years
Sponsor
REGENXBIO Inc.
Enrollment
200 participants
Start Date
Dec 20, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
Eligibility
Sex: MALEMin Age: 0 YearsMax Age: 25 Years
Inclusion Criteria3
- Males at least 0 to <25 years of age
- Diagnosis of DMD
- Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements
Exclusion Criteria1
- Prior participation in a gene therapy trial OR recipient of a gene therapy drug
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTAAV8 DetectCDx
An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05683379
Related Trials
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT0681738210 locations
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT0728718921 locations
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT071606345 locations
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
NCT061241961 location
Vasodilator and Exercise Study for DMD (VASO-REx)
NCT062907131 location